Please check your internet connection and try again.
# Walethmade bromide
## Overview
Walethmade bromide is a synthetic opioid analgesic.
## Primary Indications
* Moderate to severe pain management.
## Adult Dosing
* **Oral:** 10-30 mg every 4-6 hours as needed. Maximum dose is not explicitly established but should be guided by patient response and opioid tolerance.
* **Parenteral:** 5-15 mg every 4-6 hours as needed. Maximum dose is not explicitly established but should be guided by patient response and opioid tolerance.
Specific dosing and frequency for acute vs. chronic pain, or in opioid-naïve vs. opioid-tolerant patients, will depend on local protocol and individual patient assessment.
## Pediatric Dosing
* Data on pediatric dosing is limited. Use is generally not recommended in pediatric patients unless benefits outweigh risks and under expert guidance.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Lower doses and increased monitoring may be necessary. Start with the lowest effective dose.
* **Renal Impairment:** Use with caution. May require dose reduction and increased monitoring, especially in severe impairment. Start with the lowest effective dose.
## Contraindications
* Known hypersensitivity to walethmade bromide or other opioids.
* Significant respiratory depression.
* Gastrointestinal obstruction or ileus.
* Acute or severe bronchial asthma or hypercapnia.
## Adverse Effects
* **Common:** Constipation, nausea, vomiting, drowsiness, dizziness, pruritus.
* **Serious:** Respiratory depression, CNS depression, constipation leading to impaction, opioid-induced hyperalgesia, addiction, overdose.
## Key Drug Interactions
* **CNS Depressants (e.g., benzodiazepines, alcohol, sedatives, hypnotics):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **MAO Inhibitors:** Potentially severe and unpredictable reactions. Avoid concurrent use and for 14 days after discontinuing MAO inhibitors.
* **CYP3A4 Inhibitors/Inducers:** May alter walethmade bromide plasma concentrations.
## Monitoring
* Pain intensity and relief.
* Respiratory rate and depth.
* Sedation level.
* Bowel function.
* Signs of potential misuse or addiction.
## Clinical Pearls
* Titrate dose to the lowest effective level to minimize adverse effects.
* Consider the use of bowel regimens proactively for patients receiving regular doses.
* Educate patients on the risks of dependence, addiction, and overdose.
* Ensure naloxone is readily available for patients at increased risk of opioid overdose.
***
**Disclaimer:** This information is intended for clinical decision support and does not replace professional medical advice. Always consult the most current prescribing information and institutional guidelines before administering any medication.
